News stories about Eyegate Pharmaceuticals (NASDAQ:EYEG) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eyegate Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.8049785786655 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Eyegate Pharmaceuticals (NASDAQ:EYEG) traded up 6.00% during mid-day trading on Friday, reaching $1.06. 194,576 shares of the company were exchanged. Eyegate Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $3.90. The company’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.80. The stock’s market capitalization is $18.24 million.

A number of analysts recently commented on the stock. HC Wainwright set a $6.00 price objective on shares of Eyegate Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Noble Financial reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th.

TRADEMARK VIOLATION WARNING: “Eyegate Pharmaceuticals (EYEG) Receiving Somewhat Positive Press Coverage, Study Finds” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Insider Buying and Selling by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.